- Company
- 'Keytruda' attempts at reimbursement for TNBC
- by Whang, byung-woo Sep 24, 2024 05:46am
- The industry watches whether Keytruda (pembrolizumab), which demonstrated treatment benefits in early triple-negative breast cancer, will pass the reimbursement hurdle. As the Cancer Disease Review Committee (CDRC) of the Health Insurance Review and Assessment Service (HIRA) convenes in October, whether Keytruda will set a ground to expand 17
- Company
- Samsung Bioepis’ Opuviz recommended for approval in Europe
- by Whang, byung-woo Sep 24, 2024 05:46am
- Samsung Bioepis announced on the 23rd that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the company’s Eylea biosimilar ‘Opuviz (aflibercept).’ The EMA CHMP’s positive opinion plays a crucial role in the marketing authorization review process by the Euro
- Policy
- Pharmbio releases first generic Revolade with reimb in OCT
- by Lee, Tak-Sun Sep 24, 2024 05:46am
- The first generic version of the immune thrombocytopenia treatment ‘Revolade&160;(eltrombopag&160;olamine)’ will be released into the market in October. Pharmbio Korea’s Revolade generic has succeeded in receiving reimbursement listing 1 year after its approval in Korea. The company had been delaying its launch due to the burden of p
- Company
- Will Wegovy launch in KOR continue the Saxenda syndrome?
- by Moon, sung-ho Sep 24, 2024 05:46am
- 'Wegovy,' an obesity drug that is hugely popular but in shortages worldwide, will land in South Korea in mid-October. It will become domestically available a year and a half after receiving approval from the Ministry of Food and Drug Safety (MFDS). It marks the ninth release worldwide, following Japan and China. The Wegovy effect has garn
- Company
- Severe asthma biologic 'Nucala' available in the 'Big 5'
- by Eo, Yun-Ho Sep 24, 2024 05:46am
- The biologic antibody drug 'Nucala' is now available for prescription at tertiary general hospitals. According to industry sources, GSK's Nucala (mepolizumab), a treatment for severe neutrophilic asthma, has passed the drug committees of the 'Big 5' tertiary hospitals, including Samsung Medical Center, Seoul University Hospital, Seoul As
- Company
- Hugelsets sights on Indonesia with botulinum toxin Letybo
- by 어윤호 Sep 23, 2024 09:40am
- Hugel Inc., a leading global medical aesthetics company, said on Monday it had hosted a launch event of Letybo last week at Shangri-La Jakarta in Indonesia, the second-largest medical aesthetics market in Southeast Asia, to promote the clinical efficacy of the botulinum toxin. The event comprised online and on-site lectures on techniques a
- Company
- Why royalties for Yuhan’s Leclaza were reduced $300mil
- by Chon, Seung-Hyun Sep 23, 2024 05:51am
- The maximum contract amount for Leclaza, which was licensed out to Janssen by Yuhan Corp, has been reduced by USD 350 million. This reduction was due to the termination of research to develop Leclaza as a next-generation anti-cancer drug. Yuhan Corp received USD 210 million as upfront payment and development and approval milestones for the licen
- Company
- Will the high-priced Hemgenix be reimbursed in Korea?
- by Whang, byung-woo Sep 23, 2024 05:50am
- The reimbursement listing process for Hemgenix (etranacogene dezaparvovec-drlb), a 'one-shot' treatment for hemophilia B that shows its effect as a single dose that received domestic approval recently, has been gaining attention in Korea. According to industry sources on the 21st, the Ministry of Food and Drug Safety (MFDS) recently appro
- InterView
- "An OTC drug increases lymphedema patient satisfaction"
- by Kim, Jin-Gu Sep 23, 2024 05:50am
- Lymphedema occurs when the body's flow of lymph fluid is disrupted. Due to a particular reason, the build-up of lymph fluid between cells causes swelling and hardening of fatty tissues in the arms and legs. Unfortunately, the number of medicines for treating lymphedema is limited. Therefore, there are unmet needs in clinical practices. Hence
- Company
- Will restrictions on oral SMA drug Evrysdi be lifted?
- by Eo, Yun-Ho Sep 23, 2024 05:50am
- Whether the prescription restrictions set on the oral spinal muscular atrophy (SMA) treatment ‘Evrysdi’ may be lifted is gaining attention in Korea. According to Dailypharm coverage, Roche Korea applied to expand the reimbursement of its SMA treatment Evrysdi (risdiplam), which is currently allowed up to 2 bottles per day, and the agend
